CRIS - Curis Corp P/S Multiple

Corporate company logo of curis.com (CRIS)

Curis, Inc. minimizes capital expenditures by outsourcing clinical trials to third-party organizations. The price-to-sales trend clearly demonstrates a smooth market valuation, where the parameter value equals 0.90. The company generates stable passive income from royalties for targeted therapy. However, a high dependence on the outcomes of a few drug trials creates significant binary risks for investors.

CRIS: Curis Corp P/S Multiple 07/04/2022 - 11/13/2026

Curis, Inc. (CRIS) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Quotes curis.com|CRIS - Consensus Target
- market capitalization statistics:
Market Capitalization Curis Corp|CRIS - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Curis|CRIS - Book Capitalization|Market Capitalization to Book Value curis.com|CRIS - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Curis, Inc.|CRIS - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital curis.com|CRIS - Company Aggregate Debts|Debts to Net Assets Curis Corp|CRIS - Company Long-Term Debt|Company Short-Term Indebtedness Curis|Quick Liquidity Indicator curis.com
- earnings and valuation multiples information:
CRIS - Net Income|Company Profit Forecast Curis, Inc.|CRIS - P/E Multiple|Projected Price to Earnings curis.com|CRIS - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Curis Corp|CRIS - Operating profit EBITDA|Net earnings per share for the last four quarters Curis|CRIS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months curis.com|CRIS - Earnings growth in current year|Expected earnings per share growth for next year Curis, Inc.
- issuer revenue and sales details:
CRIS - Revenue and Sales Volume|Projected Sales Volume curis.com|CRIS - Price-to-Revenue Ratio|Market Cap to Projected Revenue Curis Corp
General company analysis:CRIS, Curis Inc.
Core merchandise of Curis

Curis, Inc. (CRIS) focuses on high-tech developments in targeted oncology, where business value is driven by the potential of the R&D pipeline. This metric compares the company's market capitalization with its current revenues, quantifying market expectations regarding the future commercialization of drugs. The P/S ratio measures the premium investors are willing to pay per unit of revenue, identifying whether the asset is overvalued or undervalued. The price-to-sales ratio trend helps assess market optimism amid ongoing clinical trials.

Competitors of Curis, Inc.

Market Cap to Revenue beigene.com ONC|Halozyme - Market Cap to Revenue|P/S Multiple Revolution Medicines Inc RVMD|AAPG - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio CGON (CG Oncology Therapeutics)|URGN: P/S Multiple|BCAX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Personalis|Erasca Inc (ERAS) - Price-to-Revenue Coefficient|Market Cap to Revenue DCTH (Delcath)|YMAB (Y-mAbs Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple AURA (Aura Biosciences, Inc.)|Price-to-Revenue Coefficient Candel Therapeutics Inc. (CADL)|ARAY - Price-to-Revenue Ratio|SLS (SELLAS Life Sciences) - Market Cap to Revenue Ratio|ACTU: P/S Multiple|Market Cap to Revenue Citius Oncology Inc|Market Cap to Revenue HURA|protaratx.com (TARA) - Price-to-Revenue Coefficient|P/S Multiple FATE|Market Cap to Revenue aadibio.com WHWK|Price-to-Revenue Ratio TScan Therapeutics, Inc. TCRX|Market Capitalization-to-Revenue Ratio CSBR|XBiotech USA - P/S Multiple|Price-to-Revenue Coefficient CEL-SCI Corporation CVM|OS Therapies (OSTX) - Price-to-Revenue Ratio|RADX - Price-to-Revenue Coefficient|ARTV (Artiva Biotherapeutics Inc.) - P/S Multiple|Market Cap to Revenue Adlai Nortye Limited (ANL)|P/S Multiple VERU|P/S Multiple tempesttx.com (TPST)|Price-to-Revenue Ratio Xilio Therapeutics XLO|RENB: Market Cap to Revenue Ratio|Mural Bio - P/S Multiple|Kairos Pharma Ltd (KAPA) - Market Cap to Revenue|OKUR: P/S Multiple|Price to Sales CytoMed Therapeutics Limited (GDTC)|Price-to-Revenue Ratio Apollomics Inc.|THAR: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue ADVB (Advanced Biomed Inc)|GNPX (Genprex Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Market Cap to Revenue|XBIO: Market Cap to Revenue|SLRX - P/S Multiple|Purple Biotech Corp (PPBT) - Price-to-Revenue Ratio|American Oncology Network, Inc. - Market Capitalization-to-Revenue Ratio|BGNE (BeiGene, Ltd.) - P/S Multiple|Price to Sales checkpointtx.com CKPT|P/S Multiple ELEV|Market Cap to Revenue icadmed.com ICAD|Ikena Oncology - Market Cap to Revenue|P/S Multiple Notable Labs Corp NTBL|VIRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MOR (morphosys.com)|NAYA: P/S Multiple|AAPGV - Price-to-Revenue Coefficient